Dilara Perver

I am the CEO and co-founder of Humaniche, an ETH Zürich biotech spin-off in formation, developing predictive human bone marrow models as microenvironment-mimetic pre-clinical test platforms to improve decision-making in blood cancer drug development. Our systems enable more reliable evaluation of hematopoietic toxicity and efficacy for advanced therapies, including cell and gene therapies, ADCs, and targeted oncology drugs. My background combines biomedical engineering from ETH Zürich, clinical trial management training, and an MBA at the University of St. Gallen, supporting a strong focus on portfolio strategy, evidence generation, and commercialization of research technologies. I am particularly interested in collaborations with pharma, biotech, and CDMOs working on predictive preclinical systems, advanced therapy development, and next-generation testing approaches aligned with emerging regulatory expectations.